Monoclonal antibodyFDA-approvedSecond-line
Erbitux
Generic name: cetuximab
How it works
Blocks the epidermal growth factor receptor (EGFR) on cancer cells, preventing them from growing and dividing.
Cancer types
Colorectal Cancer— EGFR-expressing
Efficacy
Studies show that Erbitux can improve response rates and progression-free survival in patients with metastatic colorectal cancer who have not responded to chemotherapy.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing a New Treatment for Colorectal Cancer | Colorectal Cancer | phase-1 | — | Source → |
| Study of a New Treatment for Advanced Colorectal Cancer | Colorectal Cancer | phase-3 | — | Source → |
| Study of Combination Therapy for Metastatic Colorectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Testing IBI351 with Cetuximab in Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing a New Medicine for Advanced Solid Tumors with KRAS Mutations | Lung Cancer | phase-1 | — | Source → |
| Combining Treatments for Lung Cancer | Lung Cancer | lab-study | Response rates of 41% and 49% and median progression-free survival of 6.3 and 9.7 months. | Source → |
| New Treatment Option for Chinese Patients with Aggressive Colorectal Cancer | Colorectal Cancer | phase-2 | The Doublet arm demonstrated superior progression-free survival of 4.2 months vs. 2.5 months in the Control arm. | Source → |
| Succinate Helps Cancer Cells Resist Treatment | Colorectal Cancer | lab-study | — | Source → |
| Butyrate May Reduce Effectiveness of Colorectal Cancer Treatment | Colorectal Cancer | lab-study | — | Source → |
| Machine Learning Predicts Cancer Treatment Outcomes | Colorectal Cancer | phase-3 | Higher toxicity clusters were associated with improved overall survival and progression-free survival outcomes (adjusted hazard ratios ranging from 2.21 to 4.36) and higher CET concentrations (p = .003). | Source → |
| RAS Mutations in Blood Linked to Poorer Outcomes in Colorectal Cancer | Colorectal Cancer | phase-2 | The presence of ctDNA RAS mutations at any time point was significantly associated with poorer progression-free survival (adjusted HR = 2.24, P = .02). | Source → |
| Woman with Advanced Colon Cancer Treated with Chemotherapy | Colorectal Cancer | observational | — | Source → |
| Rare Cancer Complication Found in Patient with BRAF Mutated Colon Cancer | Colorectal Cancer | observational | — | Source → |
| Comparing Two Cancer Treatments in Metastatic Colorectal Cancer | Colorectal Cancer | phase-3 | There was no significant difference in median overall survival between treatment groups (9.1 months vs 10.1 months). | Source → |
| Combining Chemotherapy and Anti-EGFR Antibody May Help Some Colorectal Cancer Patients | Colorectal Cancer | meta-analysis | The pooled objective response rate was 85% (95% CI, 0.78-0.91; I = 58%) and the pooled rate of R0 resection was 42% (95% CI, 0.32-0.53; I = 62%). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.